A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

This Phase I study is testing a new type of CAR T-cell therapy — immune cells from the patient's own blood that are engineered to target a protein called BCMA on cancer cells — in patients with advanced multiple myeloma or diffuse large B-cell lymphoma (DLBCL) that has relapsed or stopped responding to multiple prior treatments. The study is primarily focused on establishing safety and the right dose. **You may be eligible if...** - You are 18 or older with either multiple myeloma or aggressive B-cell lymphoma that has relapsed or stopped responding to treatment - For myeloma: you have received at least 2 prior lines of therapy including specific drug classes - For lymphoma: your cancer has relapsed or failed standard salvage chemotherapy, autologous transplant, or other approved therapies - Your general health allows participation (ECOG score 0–2) - Your organ function meets minimum requirements **You may NOT be eligible if...** - You have active uncontrolled infections - You have severe heart, lung, or liver problems - Your cancer has spread to the brain - You have other serious medical conditions that make the treatment too risky Talk to your doctor to see if this trial is right for you.